611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Study Finds 31 Percent Use No Opioids After SurgeryNewly Designed Pulsed-Dye Laser Found Effective for RosaceaA Big Belly Bad for Your HeartWrist Device Shows Promise for Hand TremorsHealth Tip: Learn Symptoms of AppendicitisAAN: Erenumab Shows Promise for Hard-to-Treat MigraineDrinking May Worsen Hearing Loss at Loud ConcertsHis and Her Knee Injuries Occur the Same WayMild TBI May Increase Risk of Parkinson's DiseaseJust One Concussion Could Raise Parkinson's RiskGene Twist Can Make Your Blood Pressure Spike From SaltCould Banned Chemicals Be Lurking in Your Kitchen?More Than 40% of Americans Breathe Dirty Air: ReportCaffeine Does Not Appear to Be Linked to Risk of ArrhythmiaNew Therapy May Prevent Tough-to-Treat MigrainesHealth Tip: Understanding Allergy Blood TestingSimilar Outcomes for Transplant With Overdose-Death DonorsCan 'Mono' Virus Up Odds for 7 Other Diseases?n-3 Fatty Acids Don't Seem to Be of Any Benefit in Dry Eye DiseaseNegative Affect That Lingers Tied to Health 10 Years LaterIt Costs $2.2 Billion a Year to Treat Antibiotic ResistanceHealth Tip: Using Glaucoma Eye DropsWhat You Need to Know About Fever in AdultsMany Providers Unaware of Racial Disparities in Kidney TransplantsSpring Sneezin' Season Has SprungZika May Linger in Semen for Shorter Period Than Thought: StudyPeanut Allergy Vaccine Works -- in MiceGot Osteoarthritis? Get MovingNew Staging System Predicts CKD Progression in ChildrenMetabolic Syndrome Common in Patients With LupusFirst Auto-Darken Contact Lenses ApprovedExercise Best Defense for Those at Genetic Risk for CVDPharmacists Play Role in Cutting Hospital-Acquired InfectionsAHA: Asthma as Kid, Stiffer Arteries as an Adult?Kratom-Linked Salmonella Outbreak Widens: CDCSometimes, Headaches Can Be an Emergency. Here's When.'Magnetic Pulse' Device May Be New Way to Prevent MigrainesAHA: Can Statins Help Prevent Brain Aneurysms From Rupturing?Seeking Cheaper Plastic Surgery Abroad? Buyer BewareDemoralization Common in Patients With Parkinson's DiseaseZika Infection After Birth May Require Long-Term Follow-Up2 Out of 3 Tanning Bed Users Have Never Had a Skin Cancer CheckEarly Promise for Eye Implant to Fight Macular DegenerationHealth Tip: Don't Get Burned by Kitchen AccidentsObesity Can Lead to Liver Damage by Age 8: StudyNoninvasive Brain Stimulation May Help Prevent MigrainesDiabetes, HbA1c Linked to Adverse Outcomes After SurgeryAHA: Gene Test Predicts Who Won't Benefit From Blood Thinner Plavix'Nightmare Superbug' Outbreak Could Happen, CDC WarnsHealth Tip: Treating Rosacea
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

First Drug Approved for Rare Condition That Inflames Blood Vessels

HealthDay News
by -- Scott Roberts
Updated: Dec 12th 2017

TUESDAY, Dec. 12, 2017 (HealthDay News) -- Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration as the first remedy to treat adults with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease that leads to inflammation of the blood vessels.

Other symptoms of the condition, formerly called Churg-Stress syndrome, include asthma and an overabundance of an infection-fighting white blood cell called an eosinophil. The inflamed blood vessels may affect the lungs, intestines, skin, heart and nervous system.

The condition affects a total of about 11 out of every one million people in United States, the FDA said Tuesday in a news release.

"Patients taking Nucala in clinical trials reported a significant improvement in their symptoms," said Dr. Badrul Chowdhury, director of the FDA's Division of Pulmonary, Allergy and Rheumatology Products.

Nucala, a once-monthly injection, was first approved in 2015 to treat people 12 and older with a certain type of severe asthma, the FDA said. The drug's most common side effects include headache, injection-site reaction, back pain and fatigue.

People who are prone to a "hypersensitive" allergic reaction shouldn't take the drug, and those who are taking an inhaled corticosteroid medication to treat asthma should not abruptly stop the asthma remedy, the agency warned.

Nucala is produced by the British pharma firm GlaxoSmithKline, whose U.S. headquarters are in Warren, N.J.

More information

Visit the FDA to learn more.